The 8th Annual Microbiome Connect: Europe 2022 dedicated to showcasing the leading drug development and consumer product platforms applying live microbial consortia, engineered microbes, and microbial-derived metabolites for therapeutic and health applications in patients and consumers.

As the first EMA approved microbiome-targeted therapeutics emerge on the horizon, drug developers will have to opportunity to benchmark their rational drug platforms, targeting validated pathways in gastrointestinal, neurological, metabolic disorders, as well as oncology-based indications.

Furthermore, there will be separate tracks dedicated to developing novel, clinical-validated product formulations for nutritional, digestive wellness, oral and skincare applications.

Join the microbiome field to hear from biotechs, pharma voices, investment bodies, consumer product brands and more, on how to develop robust, scalable, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market.

To know more visit: https://hubs.ly/Q012R7H40